Are there any criticisms or challenges associated with Annex IV?
While Annex IV simplifies the regulatory process for certain substances, it is not without criticism:
- Data Sufficiency: Some experts argue that the criteria for inclusion might not always account for long-term or subtle effects that may not be well-documented.
- Technological Advances: As science and technology advance, new data may emerge, necessitating the re-evaluation of substances previously considered safe.
- Regulatory Harmonization: There are challenges in ensuring consistency and harmonization with other international regulatory frameworks, which might have different safety thresholds.
